Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ASCO: Spotlight shines on PARP inhibitors, but no star emerges

This article was originally published in Scrip

Executive Summary

The side effects of drugs that inhibit poly ADP-ribose polymerase (PARP) are so tolerable and their activity in BRCA-positive tumors is so remarkable that cancer patients are seeking out clinical trials and clinicians are eager to enroll women with breast and ovarian cancer in the studies.

You may also be interested in...



Tesaro Doubles On Super NOVA Data, Lifts PARP Competitors

Tesaro Inc.'s stock price more than doubled on June 29 after the company reported positive progression-free survival (PFS) data for its PARP inhibitor niraparib in the Phase III NOVA clinical trial, which tripled PFS for some women with ovarian cancer compared with placebo – a result that lifted the values of competing firms.

ReCode Combines With TranscripTx, Raises $80m For Novel RNA Drugs

ReCode, whose platform allows for organ-specific delivery of RNA therapies, plans to start clinical trials in 2022 for its two lead programs in primary ciliary dyskinesia and cystic fibrosis.

Finance Watch: Biotech Stocks Down, But Holding Up Better Than Broader Indices

Public Company Edition: Benefitting from hope that biopharma interventions will help the coronavirus pandemic, the industry is faring better than others in the stock market, including the ability to launch IPOs. Also, BridgeBio leads recent financings and PDL is on track to dissolve by year-end.

Topics

Related Companies

UsernamePublicRestriction

Register

SC021617

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel